There are continuous updates to this page, keep checking back to review the latest programme. Confirmed plenary speakers include:
Centre for Public Health Nutrition Research and Centre for Research into Cancer Preventions and Screening, University of Dundee, UK
Michigan Center for Translational Pathology, USA
Matthew J. Ellis
Baylor College of Medicine, USA
Integrative Cancer Immunology Laboratory, INSERM, France
Nuffield Department of Surgical Sciences, University of Oxford
Cicely Saunders Institute, King’s College London, UK
University of Cambridge, UK
Dana-Farber Cancer Institute and Harvard Medical School, USA
The Netherlands Cancer Institute, Netherlands
Bin Tean Teh
National Cancer Centre and DUKE-NUS Medical School, Singapore
Massachusetts General Hospital and Harvard Medical School, USA
Dr. Zietman received his undergraduate training at Oxford University in the UK and then went to medical school at the Middlesex Hospital, London University graduating in 1983. After residencies in internal medicine and clinical oncology he moved to the Massachusetts General Hospital in Boston, USA for a fellowship in radiation biology. Since joining the staff of the MGH he has authored over 200 original articles, reviews, and editorials on many aspects of GU cancer. His particular research interests are in the specific roles of active surveillance, brachytherapy, hormone therapy, and proton beam therapy in the treatment of prostate cancer. He also has a long-standing interest in the organ-sparing management of bladder cancer.
He is currently Shipley Professor of Radiation Oncology at Harvard Medical School and Program Director for the Harvard Radiation Oncology Residency. He is past-President and Chair of ASTRO and a former Chair of the NCI GU Cancer Steering Committee. Since 2011, has been the Editor-in-Chief of the International Journal of Radiation Oncology Biology Physics.